In this episode, Dr Choo discusses some key abstracts presented during the virtual ASCO and WCGIC congresses in 2021.
Dr Choo comments that despite the promising and positive data with hepatic arterial infusion chemotherapy (HAIC) in two different Phase 3 trials settings, the impact on clinical practice is still questionable.
Dr Choo reviews some updated data from IMbrave150 which is the study that validated atezolizumab+bevacizumab combination as the new standard of care in 1L setting for aHCC patients. In addition, real-world data from OPTIMIS and GIDEON studies, confirmed that sorafenib has still a role to play in 1L specifically in Child-Pugh B patients.
Dr Choo emphasises that biomarkers are urgently needed in HCC and summarises several studies investigating potential biomarkers that would require further investigation prior to clinical practice validation.
Finally, Dr Choo completes the overview by presenting a Japanese study that provides support for radio frequency ablation as an option, apart from surgery for patients with small HCC.
Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO...
How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key...
In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient...